University of Michigan

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Michigan sits in the top decile of US sponsors by registered trial count (#19 of 15,742 sponsors by registered trial count).

1,327 total trials 179 currently recruiting 971 completed early-phase tilt top decile by trial count

University of Michigan: 1,327 sponsored US clinical trials, 179 recruiting.

University of Michigan sponsors 1,327 registered US clinical trials on ClinicalTrials.gov, 179 of them currently recruiting, and 971 completed. 94 of these trials are in Phase 3-4 (later-stage) and 159 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 15 trials.

Top-decile sponsor footprint

University of Michigan ranks in the top decile of sponsors by registered trial count (#19 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 64/100

971 of 1,083 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,327 total, page 27 of 27

COMPLETED Phase 2

Youth-Nominated Support Team Intervention for Suicidal Adolescents

NCT00071617

COMPLETED NA

Radiofrequency Catheter Ablation for Chronic Atrial Fibrillation

NCT00272636

COMPLETED Phase 1

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

NCT00056875

TERMINATED NA

Finger Imaging to Detect Blood Flow in the Fingertips

NCT00727480

COMPLETED Phase 1

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428

COMPLETED NA

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

NCT00721435

COMPLETED NA

Developing Identity: An Eating Disorder Randomized Clinical Trial

NCT01517906

COMPLETED NA

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

NCT00549874

COMPLETED Phase 2

Treating Periodontal Infection: Effects on Glycemic

NCT00016835

COMPLETED NA

Prostate Cancer: Family Care for Patients and Spouses

NCT00708968

COMPLETED NA

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801

COMPLETED Phase 2

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405

COMPLETED NA

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

NCT00422396

COMPLETED Phase 2

Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin

NCT00272610

COMPLETED Phase 3

Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up

NCT00506766

COMPLETED Phase 3

Prevent Inability To Control Urination

NCT00075114

TERMINATED Phase 1

Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

NCT00129415

COMPLETED NA

Digital Mammography: Computer-Aided Breast Cancer Diagnosis

NCT00732433

COMPLETED NA

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

NCT00721903

COMPLETED NA

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

NCT01530126

COMPLETED Phase 3

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207

COMPLETED

Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)

NCT00724191

COMPLETED

Behavioral Effects of Obstructive Sleep Apnea in Children

NCT00060723

COMPLETED NA

Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

NCT00004414

COMPLETED NA

Arthritis Patient Education for Urban African Americans

NCT00000396

TERMINATED NA

UVA1 Light for Scleroderma and Similar Conditions

NCT00476697

COMPLETED Phase 3

Promoting Effective Recovery From Labor Urinary Incontinence (PERL)

NCT00506116

← Previous Page 27 of 27

Phase Distribution

PhaseTrial count
Phase 1 79
Phase 2 80
Phase 3 25
Phase 4 69

What is open in the University of Michigan pipeline

179 recruiting of 1,327 indexed (13% open); 971 completed (73%).

Phase mix: 94 late (III/IV) vs 159 early (I/II) (early-phase heavy).

Top condition: Depression (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Michigan: open-pipeline peers nationwide

Peers matched on 1,327 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15%20%25% Total trials Recruiting share University of MichiganEli Lilly and CompanyGlaxoSmithKlineAstraZenecaUniversity of Colorado, DenverWayne State UniversityCase Comprehensive Cancer CenterAlbany Medical CollegeTaiho Oncology
University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Michigan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,327 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this University of Michigan page

1,327 registered trials is a research-attention snapshot, not an endorsement of University of Michigan or any single study.

  • 179 of University of Michigan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of Michigan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Michigan pipeline card: 1,327 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.